1. Pfizer faces scrutiny over alleged vaccine trial delays related to the 2020 election. 2. A former executive has been subpoenaed in an ongoing investigation.
Similar past allegations or investigations often negatively impacted stock prices, as seen with other pharma stocks. This investigation could raise worries about regulatory risks and public trust.
The investigation relates directly to the COVID-19 vaccine, a significant part of PFE's business and public perception. Thus, the likelihood of affecting PFE's stock price is high due to potential legal ramifications and market sentiment.
The immediate impact is likely as news spreads and fear may drive PFE's stock down. Regulatory investigations often lead to short-term price volatility.